Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 191
    records per page




    T cell anergy in COVID-19 reflects virus persistence and poor outcomes

    Authors: Kerstin Renner; Christine Mueller; Charlotte Tiefenboeck; Jan-Niklas Salewski; Frederike Winter; Simone Buchtler; Maximilian V Malfertheiner; Matthias Lubnow; Dirk Lunz; Bernhard Graf; Florian Hitzenbichler; Frank Hanses; Hendrik Poeck; Marina Kreutz; Evelyn Orso; Ralph Burkhardt; Tanja Niedermair; Christoph Brochhausen; Andre Gessner; Bernd Salzberger; Matthias Mack; Christine Goffinet; Florian Kurth; Martin Witzenrath; Maria Theresa Völker; Sarah Dorothea Müller; Uwe Gerd Liebert; Naveed Ishaque; Lars Kaderali; Leif Erik Sander; Sven Laudi; Christian Drosten; Roland Eils; Christian Conrad; Ulf Landmesser; Irina Lehmann

    doi:10.1101/2020.09.21.20198671 Date: 2020-09-23 Source: medRxiv

    Coronavirus disease MESHD 2019 (COVID-19) can lead to severe pneumonia HP pneumonia MESHD and hyperinflammation. So far, insufficient MESHD or excessive T cell responses were described in patients. We applied novel approaches to analyze T cell reactivity and showed that T anergy is already present in non-ventilated COVID-19 patients, very pronounced in ventilated patients, strongly associated with virus persistence and reversible with clinical recovery. T cell activation was measured by downstream effects on responder cells like basophils, plasmacytoid dendritic cells, monocytes and neutrophils in whole blood SERO and proved to be much more meaningful than classical readouts with PBMCs. Monocytes responded stronger in males TRANS than females TRANS and IL-2 partially reversed T cell anergy. Downstream markers of T cell anergy were also found in fresh blood SERO samples of critically ill MESHD patients with severe T cell anergy. Based on our data we were able to develop a score to predict fatal outcomes and to identify patients that may benefit from strategies to overcome T cell anergy.

    Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia HP pneumonia MESHD.

    Authors: Ruth Massey; Karen Wynter; Yvonne Hauck; Vidanka Vasilevski; Lesley Kuliukas; Alyce Wilson; Rebecca A Szabo; Caroline Homer; Linda Sweet; Claire Strain-Damerell; Petra Lukacik; - Covid-Moonshot Consortium; Haim Barr; Martin A. Walsh; Frank von Delft; Nir London; Anthony Finkelstein; David G Bonsall; Lucie Abeler-Dorner; Christophe Fraser; Neil M Ferguson; Swapnil Mishra; Seth Flaxman; Samir Bhatt; Oliver Ratmann; - Imperial College London COVID-19 Response Team

    doi:10.1101/2020.09.17.20190033 Date: 2020-09-22 Source: medRxiv

    The COVID-19 pandemic has brought with it the largest ever cohort of patients requiring mechanical ventilation. Here we describe such a patient who developed a recurring ventilator-associated pneumonia HP pneumonia MESHD caused by a strain of Pseudomonas aeruginosa that acquired increasing levels of antimicrobial resistance (AMR) in response to treatment. Metagenomic analysis recovered whole genomes of the bacterium directly from samples, revealing the AMR genotype. While immunological analysis of longitudinally-collected blood SERO samples revealed escalating levels of T-cell activation targeting both bacteria and virus, with evidence of bystander-activation, a feature which may have contributed to the continuing inflammation MESHD and prolonged requirement for ventilation.

    Association of Initial Symptoms or Comorbidities With Pneumonia HP Pneumonia MESHD Lesions in COVID-19 Patients: Based on Artificial Intelligence-Enabled CT Quantitation

    Authors: Fangzhengyuan Yuan; Chuan Liu; Jie Yang; Hu Tan; Shizhu Bian; Xubin Gao; Jihang Zhang; Mingdong Hu; Renzheng Chen; Yang Shen; Jingbin Ke; Yuanqi Yang; Chunyan He; Ran Cheng; Lan Huang

    doi:10.21203/rs.3.rs-78075/v1 Date: 2020-09-15 Source: ResearchSquare

    Background: Coronavirus disease 2019 (COVID-19) patients with a larger ratio of pneumonia HP pneumonia MESHD lesions are more likely to progress to acute respiratory distress syndrome MESHD respiratory distress HP syndrome and death MESHD. This study aimed to investigate the relationship of baseline parameters with pneumonia HP pneumonia MESHD lesions on admission, as quantified by an artificial intelligence (AI) algorithm using computed tomography (CT) images. Methods: This retrospective study quantitatively assessed lung lesions on CT using an AI algorithm in 1630 consecutive patients confirmed with COVID-19 on admission and classified the patients into none (0%), mild (>0–25%), intermediate (>25–50%), and severe (>50%) groups, according to the lesion ratio of the whole lung. A multivariate linear regression model was established to explore the relationship between the lesion ratio and laboratory parameters. The baseline parameters associated with lung lesions MESHD, including demographics, initial symptoms, and comorbidities, were determined using a multivariate ordinal regression model. Results: The 1630 patients confirmed with COVID-19 had a median whole lung lesion ratio of 4.1%, and the right lower lung lobe had the most lesions among the five lung lobes based on the evaluation of CT using AI algorithm. The whole lung lesion ratio was associated with the levels of plasma SERO fibrinogen (r=0.280, p<0.001), plasma SERO D-dimer (r=0.248, p<0.001), serum SERO α-hydroxybutyrate dehydrogenase (r=0.363, p<0.001), serum SERO albumin (r=-0.300, p<0.001), and peripheral blood SERO leukocyte count (r=0.194, p<0.001). Among the four patients groups categorised by whole lung lesion ratio, the highest frequency of cough HP (p<0.001) and shortness of breath MESHD (p<0.001) were found in the severe group, and the highest frequency of hypertension HP hypertension MESHD (p<0.001), diabetes MESHD (p<0.001) and anemia HP anemia MESHD (p=0.039) were observed in the intermediate group. Based on baseline ordinal regression analysis, cough HP (p=0.009), shortness of breath MESHD (p<0.001), hypertension HP hypertension MESHD (p=0.002), diabetes MESHD (p=0.005), and anemia HP anemia MESHD (p=0.006) were independent risk factors for more severe lung lesions MESHD. Conclusions: Based on AI-enabled CT quantitation, patients with initial symptoms of cough HP cough MESHD/ shortness of breath MESHD, or with comorbidities of hypertension HP hypertension MESHD, diabetes MESHD, or anemia HP anemia MESHD, had a higher risk for more severe lung lesions on admission in COVID-19 patients.

    Respiratory Rehabilitation After Blood SERO Transfusion in a COVID-19 Patient: A Case Report

    Authors: Mohammad Javad Mousavi; Narges Obeidi; Saeed keshmiri; Farzan Azodi; Jamile Kiyani; Farhad Abbasi

    doi:10.21203/rs.3.rs-78131/v1 Date: 2020-09-15 Source: ResearchSquare

    Background: The coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has been identified as the most crucial threat of the century. Due to severe pneumonia HP pneumonia MESHD and acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD), the SARS-CoV-2 can cause shortness of breath MESHD, hypoxemia HP hypoxemia MESHD, and the need to mechanical ventilation, intensive care unit (ICU) management, and eventual death MESHD. We have tried to use a non-invasive approach to prevent patient from needing respiratory support with invasive ventilation (IV). Here, for the first time, improvement of oxygen delivery and oxygen saturation levels were observed in a COVID-19 patient using packed red blood SERO cells (PRBCs) transfusion.Case presentation: A 63-year-old man with a history of smoking and addiction who came to our hospital facility with fever HP fever MESHD, shortness of breath MESHD and decreased blood SERO oxygen saturation. High-resolution chest CT revealed bilateral and multifocal ground-glass opacities consistent with COVID-19. Subsequently, the COVID-19 infection was confirmed TRANS infection was confirmed MESHD by real-time polymerase chain reaction (qRT-PCR) assay of the upper respiratory tract. Conclusions: Oxygen delivery and oxygen saturation improvement were observed in the COVID-19 patient, after PRBCs transfusions.

    Lung Mechanics in Type L CoVID-19 Pneumonia HP: A Pseudo-Normal ARDS.

    Authors: Lorenzo Viola; Emanuele Russo; Marco Benni; Emiliano Gamberini; Alessandro Circelli; Luca Bissoni; Domenico Pietro Santonastaso; Giovanni Scognamiglio; Giuliano Bolondi; Luca Mezzatesta; Vanni Agnoletti

    doi:10.21203/rs.3.rs-78234/v1 Date: 2020-09-15 Source: ResearchSquare

    Background. This study was conceived to provide systematic data about lung mechanics during early phases of CoVID-19 pneumonia HP pneumonia MESHD, as long as to explore its variations during prone positioning.Methods. We enrolled four patients hospitalized in the Intensive Care Unit of “M. Bufalini” hospital, Cesena (Italy); after the positioning of an esophageal balloon MESHD, we measured mechanical power, respiratory system and transpulmonary parameters and arterial blood SERO gases every 6 hours, just before decubitus change and 1 hour after prono-supination.Results. Both respiratory system and transpulmonary compliance and driving pressure confirmed the pseudo-normal respiratory mechanics of early CoVID-19 pneumonia HP (respectively, CRS 40.8 ml/cmH2O and DPRS 9.7 cmH2O; CL 53.1 ml/cmH2O and DPL 7.9 cmH2O). Interestingly, prone positioning involved a worsening in respiratory mechanical properties (CRS,SUP 56.3 ml/cmH2O and CRS,PR 41.5 ml/cmH2O – P 0.37; CL,SUP 80.8 ml/cmH2O and CL,PR 53.2 ml/cmH2O – P 0.23).Conclusions. Despite the severe ARDS pattern, respiratory system and lung mechanical properties during CoVID-19 pneumonia HP pneumonia MESHD are pseudo-normal and tend to worsen during pronation.Trial registration. Restrospectively registered.

    Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection MESHD In Vitro by Blocking Spike Protein-ACE2 Interaction

    Authors: ChangDong Lin; Yue Li; MengYa Yuan; MengWen Huang; Cui Liu; Hui Du; XingChao Pan; YaTing Wen; Xinyi Xu; Chenqi Xu; JianFeng Chen; Francia Reyes Silva; Sunil Acharya; Tamara Laskowski; Luis Muniz-Feliciano; Pinaki Banerjee; Ye Li; Sufang Li; Luciana Melo Garcia; Paul Lin; Hila Shaim; Sean G Yates; David Marin; Indreshpal Kaur; Sheetal Rao; Duncan Mak; Angelique Lin; Qi Miao; Jinzhuang Dou; Ken Chen; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani

    doi:10.1101/2020.09.14.295956 Date: 2020-09-15 Source: bioRxiv

    Coronavirus Disease MESHD 2019 (COVID-19) spreads globally as a sever pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). Cell entry of SARS-CoV-2 mainly depends on binding of the viral spike (S) proteins to angiotensin converting enzyme 2 (ACE2) on host cells. Therefore, repurposing of known drugs to inhibit S protein-ACE2 interaction could be a quick way to develop effective therapy for COVID-19. Using a high-throughput screening system to investigate the interaction between spike receptor binding domain (S-RBD) and ACE2 extracellular domain, we screened 3581 FDA-approved drugs and natural small molecules and identified ceftazidime as a potent compound to inhibit S-RBD-ACE2 interaction by binding to S-RBD. In addition to significantly inhibit S-RBD binding to HPAEpiC cells, ceftazidime efficiently prevented SARS-CoV-2 pseudovirus to infect ACE2-expressing 293T cells. The inhibitory concentration (IC50) was 113.2 M, which is far below the blood SERO concentration (over 300 M) of ceftazidime in patients when clinically treated with recommended dose. Notably, ceftazidime is a drug clinically used for the treatment of pneumonia HP pneumonia MESHD with minimal side effects compared with other antiviral drugs. Thus, ceftazidime has both anti-bacterial and anti-SARS-CoV-2 effects, which should be the first-line antibiotics used for the clinical treatment of COVID-19.

    Stepwise anti-inflammatory and anti-SARS-CoV-2 effects following convalescent plasma SERO therapy with full clinical recovery

    Authors: Aurelia Zimmerli; Matteo Monti; Craig Fenwick; Isabella Eckerle; Catherine Beigelman-Aubry; Celine Pellaton; Katia Jaton; Dominique Dumas; Gian-Marco Stamm; Laura Infanti; Heidrun Andreu-Ullrich; Daphne Germann; Marie Mean; Peter Vollenweider; Raphael Stadelmann; Maura Prella; Denis Comte; Benoit Guery; David Gachoud; Nathalie Rufer

    doi:10.21203/rs.3.rs-76799/v1 Date: 2020-09-12 Source: ResearchSquare

    Convalescent plasma SERO to treat coronavirus disease MESHD 2019 (COVID-19) is currently the focus of numerous clinical trials worldwide, but the criteria of treatment efficacy remain largely unknown. Here, we describe a severely immunosuppressed patient following rituximab and chemotherapy for chronic lymphoid leukemia HP lymphoid leukemia MESHD, who became infected by SARS-CoV-2. His prolonged viral disease was successfully cured after four cycles of convalescent plasma SERO. Its immunomodulatory properties led to the rapid improvement of inflammation MESHD, pneumonia HP pneumonia MESHD and blood SERO cell counts, already after the first cycle. Importantly, the cumulative increase in anti- SARS-CoV-2 neutralizing antibodies SERO following each plasma SERO transfusion was associated to progressive viral clearance, resulting in clinical recovery from infection. Our data provide insight into the different modes of action of plasma SERO components. Understanding the underlying mechanisms will help to optimize the treatment of COVID-19 patients.

    Tracheal tube obstruction MESHD due to hemoptysis HP associated with pulmonary infarction MESHD in a patient with severe COVID-19 pneumonia HP pneumonia MESHD: A case report.

    Authors: Takaaki Maruhashi; Yutaro Kurihara; Tatsuhiko Wada; Mayuko Osada; Marina Oi; Tomonari Masuda; Kunihiro Yamaoka; Yasushi Asari

    doi:10.21203/rs.3.rs-75925/v1 Date: 2020-09-11 Source: ResearchSquare

    Background: The incidence of thrombotic complications MESHD is extremely high among severe coronavirus disease MESHD 2019(COVID-19) patients in the intensive care unit. Various factors such as a cytokine storm due to an excessive immune response to inflammation MESHD, hypoxemia HP hypoxemia MESHD, and disseminated intravascular coagulation HP intravascular coagulation MESHD are considered predisposing factors for thrombotic complications MESHD.Case presentation: A 55-year-old Japanese man intubated 8 days previously was referred to our hospital because of a severe COVID-19 pneumonia HP pneumonia MESHD diagnosis after his pharyngeal swab tested positive for severe acute respiratory syndrome MESHD coronavirus 2 using reverse transcription-polymerase chain reaction. The patient continued to remain hypoxic (PaO2/FiO2 ratio <100 mmHg) at the referring hospital. On admission, we initiated veno-venous extracorporeal membrane oxygenation (VV-ECMO). Unfractionated heparin and nafamostat mesylate were used as anticoagulants during VV-ECMO. Despite the adequate anticoagulant therapy, he developed pulmonary infarction MESHD due to pulmonary embolism HP pulmonary embolism MESHD followed by hemoptysis HP. On day 10 following admission, his oxygen saturation dropped from 95% to 88%, with a marked decrease in his ventilator tidal volume, accompanied by an inability to ventilate the patient. Thereafter, we increased the VV-ECMO flow and exchanged his endotracheal tube. The lumen of the removed tracheal tube was found to be occluded by a large-sized blood SERO coagulum. There was no further episode of tube occlusion MESHD. The patient was discharged in a walkable state on day 39 following admission. Conclusions: Endotracheal tube obstruction MESHD secondary to hemoptysis HP should be suggested in patients with COVID-19 requiring ventilator support, as they are not able to perform frequent endotracheal tube suctions owing to the risk of infection TRANS risk of infection TRANS infection MESHD.

    T cell anergy in COVID-19 reflects virus persistence and poor outcomes

    Authors: Kerstin Renner; Christine Müller; Charlotte Tiefenböck; Jan-Niklas Salewski; Frederike Winter; Simone Buchtler; Maximilian Malfertheiner; Matthias Lubnow; Dirk Lunz; Bernhard Graf; Florian Hitzenbichler; Frank Hanses; Hendrik Poeck; Marina Kreutz; Evelyn Orso; Ralph Burkhardt; Tanja Niedermair; Christoph Brochhausen; Andre Gessner; Bernd Salzberger; Matthias Mack

    doi:10.21203/rs.3.rs-76318/v1 Date: 2020-09-11 Source: ResearchSquare

    Coronavirus disease MESHD 2019 (COVID-19) can lead to severe pneumonia HP pneumonia MESHD and hyperinflammation. So far, insufficient MESHD or excessive T cell responses were described in patients. We applied novel approaches to analyze T cell reactivity and showed that T anergy is already present in non-ventilated COVID-19 patients, very pronounced in ventilated patients, strongly associated with virus persistence and reversible with clinical recovery. T cell activation was measured by downstream effects on responder cells like basophils, plasmacytoid dendritic cells, monocytes and neutrophils in whole blood SERO and proved to be much more meaningful than classical readouts with PBMCs. Monocytes responded stronger in males TRANS than females TRANS and IL-2 partially reversed T cell anergy. Downstream markers of T cell anergy were also found in fresh blood SERO samples of critically ill MESHD patients with severe T cell anergy. Based on our data we were able to develop a score to predict fatal outcomes and to identify patients that may benefit from strategies to overcome T cell anergy.

    Association Between an Increase in Blood Urea Nitrogen HP Blood SERO Urea Nitrogen at 24 Hours and Worse Outcomes in COVID-19 Pneumonia HP

    Authors: Bo Ye; Hongbin Deng; Zhihui Tong; Jingjing Liang; Jing Zhou; Gang Li; Wenjian Mao; Hanwei Zhao; Lu Ke; Weiqin Li

    doi:10.21203/rs.3.rs-74258/v1 Date: 2020-09-08 Source: ResearchSquare

    Background and objectives: The dynamic change of blood SERO urea nitrogen (BUN) have been proved to be related to the worse outcomes in various diseases such as pulmonary embolism HP pulmonary embolism MESHD, acute pancreatitis HP pancreatitis MESHD and acute nonvariceal upper GI bleeding MESHD. In the present study, we aimed to identify the association between blood SERO urea nitrogen (BUN) change and clinical outcomes in patients presenting with COVID-19 pneumonia HP pneumonia MESHD.Methods: This is a retrospective study conducted in the Huoshenshan hospital. Patients with laboratory-confirmed COVID-19 from Feb 5th to March 5th in 2020 who had BUN level tested on admission and on the second day consecutively were included. Patients were stratified into two groups according to the BUN change (increase vs. no increase) during the first 24 hours. The primary outcome was in-hospital mortality. Moreover, other clinical outcomes were also compared. The potential risk factors of in-hospital mortality were analyzed. Results: There were 266 patients included in the study. The mean change in BUN at 24 hours was 1.0 mg/dL, with 206 patients (77.4%) experiencing no increase in BUN and 60 patients (22.6%) experiencing an increase in BUN. In-hospital mortality was significantly higher in the BUN increase group compared to no increase group (30.0% vs. 5.8%, P<0.001). BUN increase group also had higher requirement for ICU admission, use of invasive mechanical ventilation and incidence of AKI (all P<0.001). After adjusted for related factors, the BUN increase was independently associated with the mortality with an odds ratio of 7.427[95% CI 2.370-23.279]. In the multivariable and survival analysis, BUN increase was also found to be associated with survival regardless of the admission BUN.Conclusions: In patients with COVID-19, BUN increase at 24 hours was an independent predictor for a composite clinical outcome and in-hospital mortality. The association of BUN increase with worse outcomes further emphasizes the importance of monitoring BUN change and kidney function in the course of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.